Oxford Cannabinoid Technologies

Oxford Cannabinoid Technologies is a clinical-stage biopharmaceutical company dedicated to developing non-addictive, cannabinoid-based medicines for chronic pain management. The company's research focuses on selective agonists of the cannabinoid receptors to provide effective analgesia without the psychoactive effects or addiction potential associated with traditional opioids or medical cannabis. Its lead candidate, OCT461201, is a selective CB2 agonist that has completed Phase 1 clinical trials for neuropathic pain and irritable bowel syndrome. By combining a proprietary chemical library with academic collaborations, the company aims to transform the treatment landscape for debilitating pain conditions.